Codexis to Participate in Cowen 43rd Annual Health Care Conference
Rhea-AI Summary
Codexis, a leader in enzyme engineering, will participate in the Cowen 43rd Annual Health Care Conference from March 6-8, 2023, in Boston, Massachusetts. Stephen Dilly, CEO, will join a panel discussion on 'SynBio & AI Driven Drug Discovery' on March 6 at 4:40 pm ET. The management team will also engage in a fireside chat on March 7 at 11:10 am ET. Interested investors can access webcasts of both events on the company's Investor Relations webpage, with the panel archived for 30 days and the chat for 90 days. Codexis utilizes its CodeEvolver® platform to develop innovative enzymes and biotherapeutics for various applications, enhancing manufacturing and therapeutic efficacy.
Positive
- None.
Negative
- None.
News Market Reaction – CDXS
In the trading session that priced this news, CDXS gained 4.43%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 43rd Annual Health Care Conference, being held March 6-8, 2023, in Boston, Massachusetts.
Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis, will participate in a panel discussion titled, “SynBio & AI Driven Drug Discovery,” taking place on Monday, March 6, 2023, at 4:40 pm ET. Dr. Dilly and other members of the management team will also participate in a fireside chat taking place on Tuesday, March 7, 2023, at 11:10 am ET. Webcasts of both events will be available in the Investor Relations section of the Company’s website, http://ir.codexis.com.The panel presentation and fireside chat webcasts will be archived for 30 and 90 days, respectively, following the event.
About Codexis
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of small molecule pharmaceuticals, in RNA and DNA synthesis and the creation of next generation life science tools, and as gene therapies and oral enzyme therapies. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved return on capital in manufacturing, improved sensitivity in genomic and diagnostic applications, and more efficacious therapeutics. For more information, visit www.codexis.com.
Investor Relations Contact:
Argot Partners
Brendan Strong/Carrie McKim
(212) 600-1902
Codexis@argotpartners.com
Media Relations Contact:
Lauren Musto
(781) 572-1147
lauren.musto@codexis.com
